AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 JUN 19 - (NewsRx.com & NewsRx.net) -- Expression of the protein cyclooxygenase-2 (COX-2) but not cyclooxygenase-1 (COX-1) in breast cancer tissue is a poor prognostic factor, linked to decreased survival, according to new research.
Expression of COX-2 was also associated with such poor prognostic factors as invasion into nearby lymph nodes and blood vessels, larger tumor size, and estrogen receptor negative status. In contrast, COX-1 expression had no statistically significant impact on patient prognosis, according to the study, reported in the June 15, 2003 issue of Cancer.
Given recent evidence that drugs that inhibit COX proteins called nonsteroidal anti-inflammatory drugs (NSAIDs), such as aspirin, reduce the risk of various type of cancer, "further studies will be required to determine whether COX-2 inhibitors may be useful for therapy or prevention of breast cancer," concluded the authors, Denkert et al. who conducted their study at the Charit University Hospital in Berlin.
The American Cancer Society estimates more than 211,000 women in the United States will be diagnosed with breast cancer in 2003. To help physicians and patients choose effective treatments, scientists have identified several factors that predict disease severity. These include the presence or absence of tumor cells in lymph nodes, tumor size, estrogen receptor negative status, and characteristics of the tumor cells themselves. Increasing evidence suggests that COX proteins may also be important factors in tumor severity.
COX proteins come in two primary forms, COX-1 and COX-2 and are more commonly implicated in inflammation. COX-1 is expressed in most tissues, while COX-2 is more selectively expressed. NSAIDs unselectively inhibit COX protein synthesis and are commonly used to control inflammation-related pain.
Recent studies using NSAIDs suggest a link between COX proteins and cancer risk. Regular use of NSAIDs has been associated with an 18% reduction in the risk of breast cancer. Furthermore, animal models have shown that ...